CASRN: 2019171-69-6
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of pegcetacoplan during breastfeeding. Since only a small dose in injected intravitreally into the eye, it is unlikely that a clinically relevant amount would reach the infant in breastmilk. With the systemic administration of pegcetacoplan, the manufacturer recommends that breastfeeding be discontinued during treatment and for 40 days after the last dose. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Paroxysmal Nocturnal Hemoglobinuria) Eculizumab
Substance Identification
Substance Name
Pegcetacoplan
CAS Registry Number
2019171-69-6
Drug Class
Breast Feeding
Lactation
Milk, Human
Complement Inactivating Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Publication Details
Publication History
Last Revision: August 15, 2023.
Copyright
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Publisher
National Institute of Child Health and Human Development, Bethesda (MD)
NLM Citation
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Pegcetacoplan. [Updated 2023 Aug 15].